
AZRX
Healthcare · Biotechnology · $34.4M market cap
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Sep 30, 2021
EPS trend, 90 days to now · -1233.3% over 90 days · 30-day revisions 1 up, 0 down
Beat estimates in 4 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Aug 16, 2021 | After the close | -0.75 | -0.16 | +78.7% |
| May 24, 2021 | After the close | -0.73 | -0.14 | +80.9% |
| Mar 31, 2021 | After the close | -1.40 | -0.31 | +77.9% |
| Nov 16, 2020 | After the close | -1.32 | -0.47 | +64.5% |
| Aug 14, 2020 | After the close | -1.06 | -0.17 | +84.0% |
| May 15, 2020 | After the close | -1.13 | -0.20 | +82.4% |
| Mar 30, 2020 | After the close | -1.63 | -0.02 | +98.8% |
| Nov 14, 2019 | After the close | -1.57 | -0.17 | +89.2% |
| Aug 13, 2019 | Before the open | -2.20 | -0.25 | +88.6% |
| May 15, 2019 | After the close | -1.77 | -0.26 | +85.3% |
| Mar 31, 2019 | Time not confirmed | -0.18 | -0.24 | -33.3% |
| Nov 9, 2018 | After the close | -1.97 | -0.15 | +92.4% |
| Aug 13, 2018 | Before the open | -2.40 |
AzurRx BioPharma, Inc., a clinical stage biopharmaceutical company, focuses on the development of recombinant proteins for the treatment of gastrointestinal diseases. Its therapeutic products administer patients as oral non-systemic biologics. The company's lead therapeutic is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency. It is also developing two clinical programs using…
| -0.22 |
| +90.8% |
| May 14, 2018 | After the close | -1.80 | -0.29 | +83.9% |
| Mar 16, 2018 | After the close | -2.35 | -0.21 | +91.1% |